医学
膀胱肿瘤
随机对照试验
凝结
切除术
泌尿科
外科
激光凝固
膀胱
激光治疗
失血
临床试验
激光器
电凝
膀胱损伤
膀胱肿瘤
激光手术
放射科
作者
Gyrithe L. Pedersen,Karin Mogensen,Susanne Rosthøj,Marie Schmidt Erikson,Mikkel Fode,Gregers G. Hermann
标识
DOI:10.1097/ju.0000000000004918
摘要
PURPOSE: Ta low-grade bladder tumors, accounting for 45% of new bladder cancer cases, have considerable risk of recurrence but low risk of progression. Traditionally, treatment is burdensome and costly. Office-based laser coagulation of Ta low-grade bladder tumors is efficient, tolerable, and safe; however, long-term outcomes need to be determined. The primary objective of this study was to determine whether in-office laser coagulation of recurrent Ta low-grade bladder tumor is noninferior to standard transurethral resection of bladder tumor (TUR-BT) regarding 12-month recurrence-free survival (RFS). MATERIALS AND METHODS: Prospective, randomized, noninferiority clinical trial, performed in a hospital setting in Denmark between 2016 and 2022. Three hundred consecutive patients with recurrent Ta low-grade bladder tumor participated. Laser (photograph) coagulation of the bladder tumor (PC-BT) was performed with a 980 nm laser under local anesthesia in an office setting and compared with gold standard TUR-BT under general anesthesia. Primary outcome, 12-month RFS, was analyzed with noninferiority criterion of 15% absolute difference. Secondary outcomes included long-term RFS and stage progression. RESULTS: = .25) and only one case of stage progression was observed in each group. CONCLUSIONS: Office-based laser photograph coagulation of bladder tumor is noninferior to TUR-BT regarding 12-month RFS and is a safe, efficient treatment for recurrent Ta low-grade bladder tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI